ARTICLE | Company News
Affitech, Kael Co. Ltd. deal
March 8, 2010 8:00 AM UTC
Affitech sold its remaining rights to GV1001 to Kael's Kael-GemVax Co. Ltd. subsidiary for $1 million and will be no longer eligible for milestones and royalties. GV1001 is a cancer vaccine targetin...